Icosavax
1616 Eastlake Avenue E
Suite 208
Seattle
Washington
98102
United States
Website: http://www.icosavax.com/
26 articles with Icosavax
-
Icosavax to Participate in the Upcoming Healthcare Conferences
2/28/2023
Icosavax, Inc. today announced that the company will participate in and host one-on-one meetings at the following investor conferences.
-
Icosavax Granted FDA Fast Track Designation for IVX-A12
2/21/2023
Icosavax, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IVX-A12.
-
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
1/6/2023
Icosavax, Inc. today provided a corporate update and highlighted anticipated milestones for 2023.
-
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
12/13/2022
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV).
-
Icosavax to Participate in the Evercore ISI HealthCONx Conference
11/22/2022
Icosavax, Inc. (Nasdaq: ICVX) today announced that the company will participate in and host one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference taking place November 29 through December 1, 2022.
-
Icosavax Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
Icosavax, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Icosavax to Participate in in Upcoming Investor Conferences
11/8/2022
Icosavax, Inc. today announced that the company will participate in and host one-on-one meetings at the following investor conferences.
-
Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults
10/4/2022
Icosavax, Inc. today announced the initiation of a Phase 1 clinical trial of IVX-A12, a combination bivalent RSV and hMPV VLP vaccine candidate, in older adults.
-
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
-
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/15/2022
Icosavax, Inc. (Nasdaq: ICVX), today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones
7/28/2022
Icosavax, Inc. announced the results from an end-to-end drug product investigation of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain.
-
Icosavax to Participate in the William Blair Biotech Focus Conference
7/6/2022
Icosavax, Inc. announced that the company will participate in the William Blair Biotech Focus Conference taking place from July 12-13, 2022, in New York.
-
Icosavax posted positive topline interim data from its Phase I/Ib trial of IVX-121, its candidate virus-like particle vaccine against the respiratory syncytial virus in young and older adults.
-
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
6/28/2022
Icosavax, Inc. (Nasdaq: ICVX), today announced positive topline interim results from its Phase 1/1b clinical trial of IVX-121, a VLP displaying a prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen, in young and older adults.
-
Icosavax to Participate in the Jefferies Healthcare Conference
6/1/2022
Icosavax, Inc. announced that the company will participate in the Jefferies Healthcare Conference taking place from June 8-10, 2022.
-
Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/16/2022
Icosavax, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/30/2022
Icosavax, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Seattle-based Icosavax’s stock plunged 50% after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
-
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
3/25/2022
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).